FDA approves ARDX’s Ibsrela (tenapanor) for IBS-C—stock down 13%: https://finance.yahoo.com/news/ardelyx-receives-fda-approval-ibsrela-191200595.html Apparently something bad in the label or a kneejerk sell-on-news. ARDX has said they want a commercial partner for this drug.